ClinicaliQ Trial Snapshot
- A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas — Recruiting • Phase I • Oncology • NCT05463263.
- Drug and Mechanism: STP938 (Dencatistat) is being tested as a monotherapy agent in a dose-escalation Phase 1 study followed by Phase 2 cohort expansion across five distinct B-cell and T-cell lymphoma subtypes.
- Patient Eligibility: The trial recruits adult patients with relapsed or refractory B-cell and T-cell lymphomas, representing treatment-resistant disease populations who have exhausted standard therapeutic options.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.
Eligibility Snapshot
- Main Inclusion Criteria: * Signed and dated informed consent, and able to comply with the study procedures and any locally required authorization. * Male or female aged ≥ 18 years. * Relapsed/refractory patients with histologically confirmed diagnosis of B cell or T cell lymphoma * Must have received at least 2 prior systemic therapies and have no treatment options known to provide clinical benefit * Must have measurable disease per Lugano lymphoma classification except for cutaneous T-cell lymphoma (CTCL) which is measured via International Society for Cutaneous Lymphomas (ISCL)/ European Organization of Research and Treatment of Cancer (EORTC). * Eastern Cooperative Oncology Group (ECOG) performance status ≤2. * Life expectancy > 3 months as assessed by the Investigator. * Adequate organ function (bone marrow, hepatic, renal function and coagulation). * All toxicities (except alopecia) from prior cancer treatments or procedures must have resolved to ≤Grade 1 or returned to baseline levels prior to enrollment. Main
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.